A 34-year-old female with bipolar I disorder has been stable on olanzapine 15 mg daily for nine months, with no manic or depressive episodes since initiation. At baseline, her weight was 158 pounds with a BMI of 26.3. She now weighs 184 pounds with a BMI of 30.7, representing a 16.5% weight gain. Fasting glucose is 108 mg/dL (baseline 92), triglycerides 198 mg/dL (baseline 142), and LDL 138 mg/dL (baseline 118). She reports increased appetite, carbohydrate cravings, and decreased physical activity due to fatigue and sedation. She attempted dietary modification for the past three months with minimal effect, losing only 2 pounds before regaining them. She expresses frustration and is considering stopping the medication entirely. The PMHNP is evaluating the metabolic impact and considering intervention strategies. Which of the following best represents the appropriate evaluation?